Glaxo's data on blood-clotting drug fails to impress FDA

GlaxoSmithKline's study of Promacta does not provide "robust" evidence that the proposed drug works better than placebos in reducing bleeding in patients with chronic idiopathic thrombocytopenic purpura, the FDA announced Wednesday. GSK and partner Ligand Pharmaceuticals declined to comment on the findings, which are set to be reviewed by an expert panel Friday.

View Full Article in:

Forbes · Wall Street Journal (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Payer Marketing
Avalere Health
Washington, DC
Chief Quality Officer
UnityPoint Clinic
Des Moines, ID
Chief Medical Officer, Texas Children's Health Plan
Cejka Executive Search for Texas Childre's Health Plan
Houston, TX
The Pew Charitable Trusts
Director, Antibiotics and Innovation Project
Washington, DC
Senior Officer, Drugs and Medical Devices
The Pew Charitable Trusts
Washington, DC